| |
|
Client Experience
Over the past 13 years, Lev has advised a wide variety of companies and organizations on some of their most complex and pressing business challenges, including crises, mergers and acquisitions, turnarounds and repositioning strategies. His counsel often crosses disciplinary boundaries, weaving together insights into business strategy and securities valuation, capital formation and communication strategies. His clients have included corporate giants and small-cap stocks, industry leaders, laggards and insurgents as well as participants in “flat pyramid” competitive markets. He has also advised industry associations and foreign governments.
Large-cap |
Mid-cap |
Small-cap |
Private |
Industry Associations |
Bank of America |
Alliance Data Systems |
Affymetrix |
Cylex |
NAREIT |
BP |
Coca Cola FEMSA |
Bentley Pharmaceuticals |
New Stream Capital |
SEMI |
Citigroup |
FEMSA |
Energy Conversion |
RusAl |
Massachusetts Biotechnology Council |
Eli Lilly |
Homex |
Devices |
|
|
GSK |
Internet Security |
EpiCept |
|
|
Lilly |
Systems |
Icagen |
|
|
Novartis |
KeySpan |
InforMedix |
|
|
Pfizer |
McAfee |
Nabi Biopharmaceuticals |
|
|
Reuters |
Valassis |
Omrix |
|
|
|
VimpelCom |
Pliva/Odyssey Pharma |
|
|
|
|
RenaMed Biologics
|
|
|
|
|
Synaptic/Lundbeck |
|
|
|
|
 |
|